(SYDNEY, Wednesday, 29 April 2020) As global COVID-19 cases multiply, medical researchers fear for how the pandemic will impact the world’s most marginalised populations. In particular, people living with HIV in resource-poor, low-income countries are a critical concern, as they may be at risk of more severe outcomes from viral infections.
The Kirby Institute at UNSW Sydney will coordinate a multi-country study to determine risk factors for COVID-19 among people living with HIV, and to collect crucial information to inform strategies for clinical care in low-income countries.
The research is funded by Unitaid: Supporting innovation for global health, and ViiV Healthcare and will be conducted across up to 15 countries, through partnership with Ezintsha Wits RHI (Johannesburg, South Africa), the University of Montpellier, the French Agency for Research on AIDS and Viral Hepatitis (ANRS), the Central Hospital of Yaoundé, Cameroon, Geneva University Hospitals, and the University of Liverpool.
Globally, there are 37.9 million people living with HIV, and most people with HIV live in low-income countries, where health systems were stretched well before COVID-19.
“There is an urgent and critical need to establish how COVID-19 affects people living with HIV in low-income settings, so that we can plan for the health needs of these populations” said the Kirby Institute’s Associate Professor Mark Polizzotto, who is leading the study.
“High-income countries are struggling, and in many cases failing, to contain their COVID-19 epidemics. Where they have had success, it has been down to sophisticated public health systems, and co-ordinated, well-resourced strategies to control the movement of people,” continued Associate Professor Polizzotto. “But in low-income settings, this simply won’t be possible. People live in crowded accommodations, and without government safety nets, and it is next to impossible to stop people from going to work. Add to this the high numbers of people living with HIV, and you can understand why there’s global concern about the potential impact of COVID-19 in Africa and other resource-poor settings in our region.”
The research collaboration, the first of its kind globally, is called COHIVE, and it will bring together four existing HIV treatment trials and follow the participants on these trials who also test positive for COVID-19.
“The existing clinical trials being coordinated by this group of researchers encompass a range of HIV therapies, HIV populations, and geographic regions – including particularly vulnerable populations like pregnant women living with HIV – ensuring that we capture the full spectrum of this global public health emergency as it to relates to people living with HIV,” said Dr. Philippe Duneton, Unitaid’s Executive Director.
“This is why we have dedicated further funds to add the COVID-19 observational component to these trials. It’s exactly these kinds of collaborative innovations that Unitaid has supported for many years, and this project is one of the many ways we’ve quickly adapted to redeploy our resources to help those most vulnerable to COVID-19.”
Associate Professor Polizzotto said that the COVID-19 public health crisis requires extensive collaboration, a sharing of knowledge and most importantly an awareness of our shared humanity. “When the most disadvantaged in society have the same tools to protect themselves from COVID-19 as the wealthy, we’ll know we’ve done everything we can,” he said.
Media contact: Luci Bamford, Kirby Institute, +61 4 32 894 029 email@example.com
Interviews can be arranged with Associate Professor Mark Polizzotto
“There is no doubt that as people living with HIV we are concerned. We have compromised immune systems and therefore want very quick answers to very basic questions. We want to know how COVID-19 will affect our weak immune system? How will COVID-19 vaccines and treatment affect my HIV treatment and vice-versa? Will the vaccines be safe for me? We need to know. These planned studies are absolutely crucial towards our better understanding of COVID-19 and HIV co-infection, and they will also contribute in devising strategies of how to better care for people with HIV and COVID-19 in low- and middle-income countries”.
Kenly Sikwese, Coordinator, African Community Advisory Board (AFROCAB)
“This study will not only answer an important scientific question but also provide all the means of prevention for patients and caregivers."
Professor Eric Delaporte, PI ANRS12313 NAMSAL, University of Montpellier
“COVID-19 has left no one unaffected. As researchers working with HIV-positive pregnant women we see an urgent need to characterise and wherever possible minimise the risk of coronavirus infections in these women. Support for this research is hugely welcome, and we look forward to working with our colleagues at UNSW to address this urgent priority.”
Professor Saye Khoo, PI DOLPHIN2 University of Liverpool
“There is currently very sparse evidence relating to the possible mortality and morbidity outcomes of COVID-19 in people living with HIV. A study such as ours is of vital importance in order to inform public health systems, of how better to cope with the added disease burden that COVID-19 would present in this particular population group.”
Professor Francois Venter and Dr. Joana Woods, PIs ADVANCE, Ezintsha Wits RHI
“ViiV Healthcare has been proud to support HIV treatment trials in low- and middle-income countries through partnerships with researchers for many years. We look forward to continuing our support of this work as it expands into COVID-19.”
Dannae Brown, ViiV Healthcare
About the Kirby Institute
The Kirby Institute is a leading global research institute dedicated to the prevention and treatment of infectious diseases. Established in 1986 in response to the then emerging HIV epidemic, we now contribute to knowledge on a broad range of diseases, including viral hepatitis and sexually transmissible infections.
Unitaid brings the power of new medical discoveries to the people who most need them and helps set the stage for large-scale introduction of new health products by collaborating with governments and partners such as PEPFAR, the Global Fund and WHO. Unitaid invests in new ways to prevent, diagnose and treat diseases including HIV/AIDS, hepatitis C, tuberculosis and malaria more quickly, affordably and effectively. A growing number of our programs address more than one disease, maximizing effectiveness of health systems.